TOULOUSE, France--(BUSINESS WIRE)--Regulatory News:
VEXIM (Paris:ALVXM) (FR0011072602 ‐ ALVXM / PEA-PME eligible), a medical device company specializing in spine trauma, today announced that it has reached the key milestone of 25,000 SpineJack® units sold since the market launch of the implant in 2011.
This symbolic 25,000 mark in the sales of SpineJack® implants officially occurred in the last quarter of 2015.
In October, the company had already announced a new quaterly sales record of €3.6 million for the 3rd quarter 2015, an increase of 44% from the same period in 2014.
“To have passed the 25,000 mark in SpineJack® implants sold is a major step for Vexim, one that highlights the company’s exponential growth since we launched the device. This excellent performance was made possible by the implementation of a coherent and effective strategy, as well as the involvement of all our teams. Our technology and expertise in spine trauma are now validated by the fact that the SpineJack® is used by over 300 customers across Europe. We anticipate that the adoption of our technology will keep expanding. We’re also following on our action plan to obtain the 510(k) regulatory clearance to market SpineJack® in the U.S., which alone accounts for half of the global spine-trauma market,” said Vincent Gardès, CEO of VEXIM.
About Vexim, a leader in innovative back microsurgery
Based in Balma, near Toulouse, France, Vexim is a medical device company founded in February 2006 that specializes in the creation and marketing of minimally invasive solutions for traumatic spinal injuries (high- and low-energy trauma, tumors, etc.). Thanks to the financial support of its longstanding majority shareholder Truffle Capital1 Founded in 2001 in Paris, Truffle Capital is a leading independent European private equity firm dedicated to investing in and building technology leaders in the IT, life sciences and energy sectors. Truffle Capital manages €550m via FCPRs and FCPIs, the latter offering tax rebates (funds are blocked during 7 to 10 years). For further information, please visit www.truffle.fr and www.fcpi.fr. and to government subsidies granted by the French Public Investment Bank (BPI), Vexim has designed and developed the SpineJack®, a unique implant capable of repairing a fractured vertebra and restoring the balance of the spine. The company also developed the MasterflowTM, an innovative solution for mixing and injecting orthopedic cement that enhances the accuracy of the injection and optimizes the overall surgical procedure.
The company counts 60 employees, including its own sales teams in Europe and a network of international distributors.
Vexim has been listed on Alternext Paris since May 2012.
For further information, please visit www.vexim.com
SpineJack®, a revolutionary implant for treating Vertebral
What makes the SpineJack® such a groundbreaking technology is its ability to restore the original shape of a fractured vertebra and the optimal anatomy of the spine, thereby neutralizing the pain and allowing patients to recover their functional capabilities. Thanks to a specific set of instruments, the implant is inserted into the spine through a minimally invasive surgery, guided by X-ray, for approximately 30 minutes, which lets patients be discharged shortly after surgery. The SpineJack® product range includes 3 titanium implants of different diameters, covering 95% of all vertebral compression fractures and patients.
The SpineJack® technology is supported by leading international scientists from the field of spinal surgery and is protected by a worldwide patent through 2029.
MasterflowTM, a high-performance orthopedic cement delivery system
The MasterflowTM is an innovative solution for mixing and injecting orthopedic cement that enhances the accuracy of the injection and optimizes the overall surgical procedure for treating vertebral compression fractures. The device provides a better control of the injection of biomaterials into the spine. A complement of the Spinejack®, the MasterflowTM stands out for being both easy to use and precise, particularly in its ability to stop the cement delivery instantly without inertia. The MasterflowTM contributes to reducing pain in patients. Its first sales were recorded in the U.S. in February 2015, and the system has received the CE marking in March 2015, a mandatory conformity mark for products marketed in Europe.
1 Founded in 2001 in Paris, Truffle Capital is a leading independent European private equity firm dedicated to investing in and building technology leaders in the IT, life sciences and energy sectors. Truffle Capital manages €550m via FCPRs and FCPIs, the latter offering tax rebates (funds are blocked during 7 to 10 years). For further information, please visit www.truffle.fr and www.fcpi.fr.